Alastin Skincare^®, one of Galderma’s premium brands, is a pioneer in products specifically formulated to meet the demand for pre- and post- aesthetic procedure skincare.

Following a successful launch and growth story in the United States and Canada and more recently in Mexico, the innovative brand will soon launch in the United Kingdom. We will also transition from working with a distribution partner to direct Galderma leadership in Canada. Through this expansion, we are helping to build the future of dermatological skincare and deliver superior outcomes for patients worldwide.

The preferred skincare brand

Known as the brand of choice for peri-procedure skincare in the U.S.[1] and for scientifically-backed restorative daily skincare, Alastin has proven popular with consumers and healthcare professionals alike. Outpacing the U.S. economy is no mean feat – yet Alastin is growing at a rate six times that of the American market.[2] And its growth story continues.

On October 1, 2023, Galderma will lead Alastin expansion in two key, milestone markets: Canada and the UK. Canada, where Alastin was previously distributed through a partner, is the third-biggest physician-dispensed topicals market in the world.[3] Similarly, the UK is both the largest market for physician-dispensed topicals in Europe, as well as the fastest growing.[4] Galderma’s well-established Aesthetics business in both of these markets will bolster the awareness of Alastin and support its rapid adoption across healthcare professional and consumer audiences.

Alastin’s exciting expansion is yet another example of how Galderma’s purpose, advancing dermatology for every skin story, drives sustainable growth. Since 1981, Galderma has dedicated our focus and passion to meeting individual consumer and patient needs with superior outcomes. Following our launch as a standalone company in 2019, we have shown constant progress with year-on-year double-digit top and bottom-line growth.

Continuously expanding our global presence enables us to reach more patients in more countries. Major strategic advances like the Alastin launch will also help us achieve our bold ambition to become the leading dermatology company in the world.

The new face of peri-procedure treatments

Galderma added Alastin to our portfolio in 2022. These medical-grade products are designed to reduce signs of aging and restore a youthful appearance to the skin. They are widely used to prepare the skin before injectable treatments as well as aesthetic procedures such as laser resurfacing and body sculpting, and to promote healing and healthy skin afterwards. 

More broadly, Alastin’s natural, non-comedogenic and cruelty-free products are ideal for anyone looking to rejuvenate their skin and remedy the effects of time and other environmental stressors. TriHex Technology^® harnesses the power of a proprietary blend of peptides to support the removal of aged collagen and elastin to help jump-start the skin’s natural rejuvenation process

The science speaks for itself. Globally, more than 15 patents have already been granted to Alastin, and over 40 peer-reviewed papers have been published in journals. This brand was designed by pioneers in the field of skincare for cosmetic procedures.

Building on a strong foundation

Alastin’s growth story is a key part of Galderma’s strategy to enrich and broaden our portfolio and presence.

In the future, our teams will maintain this momentum and continue to extend the reach of our premium brands and services. Alastin is expected to launch in multiple key markets over the next two years while leveraging the established platforms and leadership reputation of Galderma.

[1] LifeSci Consulting Primary Market Research - Survey conducted 2022

[2] Kline Report 2022, North America Market Share

[3] Kline Report 2022: Global Screening Assessment

[4] Kline Report 2022, Europe Market Analysis and Opportunities.